Mayo Clinic Laboratory and pathology research roundup: June 21

By Meghann Southwick • June 21, 2022

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.

The current study was approached with the assumption that response to induction chemotherapy, in acute myeloid leukemia (AML), overshadows pre-treatment risk variables in predicting survival and therefore be used as an anchor for a simplified risk model. We considered 759 intensively-treated patients with AML, not promyelocytic: median age 60 years; primary 66%, secondary 25%, and therapy-related 9%; European LeukemiaNet cytogenetic risk category favorable 8%, intermediate 61%, and adverse 31%. Complete remission with (CR) or without (CRi) count recovery was achieved in 608 (80%) patients.

Read more.

Published to PubMed This Week

• Automation of hybridization and capture based next generation sequencing library preparation requires reduction of on-deck bead binding and heated wash temperatures.
  SLAS technology
• A systematic review supporting the endocrine society clinical practice guideline for the management of hyperglycemia in adults hospitalized for noncritical illness or undergoing elective surgical procedures.
  The Journal of clinical endocrinology and metabolism
• Outcomes of idiopathic versus secondary nodular regenerative hyperplasia of the liver: A longitudinal study of 167 cases.
  Liver International
• Frequency of asymptomatic optic nerve enhancement in a large retrospective cohort of patients with aquaporin-4+ NMOSD.
  Neurology
• Use of the esophageal sponge in directing food reintroduction in eosinophilic esophagitis.
  Clinical gastroenterology and hepatology
• Is there clinically relevant plasma interference with ELISA detection of APS antibodies? Reproducibility of real-world paired serum and plasma testing.
  Thrombosis and haemostatis
• Identification of caveolae-associated protein 4 autoantibodies as a biomarker of immune-mediated rippling muscle disease in adults.
  JAMA Neurology
• Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling.
  American Journal of cancer research
• The need to develop clinical guidance for the use of high-sensitivity cardiac troponin in pediatric and neonatal patients.
  Clinical chemistry
• A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
  American Journal of hematology

Meghann Southwick

Meghann Southwick is a marketing specialist for Mayo Clinic Laboratories. She has worked at Mayo Clinic since 2021.